id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312518-510gmyb4	Bersanelli, Melissa	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors	2020-03-26		.txt	text/plain	2460	101	33	Moreover, along with the improvement in symptoms related to systemic inflammatory response syndrome, some authors reported a clinical improvement in other irAEs with tocilizumab used in cancer patients with immune-related toxicity from anti-PD-1 agents [21, 22] . The time at which the COVID-19 patient develops the pathologic hyperactivation of the immune response, eventually contributing to the final injury, is probably in the late phase of the disease manifestation, occurring together with the respiratory distress [17] . Since ICI can restore the immune-competence, if on one hand it can be paradoxically needed to develop the cytokine storm characterizing the acute respiratory distress syndrome (ARDS) phase, on the other hand the epidemiological features of SARS-CoV-2 infection lay for a lower probability to affect these patients compared with their chemo-treated immune-suppressed counterpart. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients	./cache/cord-312518-510gmyb4.txt	./txt/cord-312518-510gmyb4.txt